Soligenix, Inc. (OTCQB: SNGX) is a clinical stage biopharmaceutical company developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics.
The Soligenix management team is led by Christopher J. Schaber, PhD. Dr. Schaber has served in this role since 2006. Prior to joining Soligenix Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc.
The Soligenix board includes Dr. Jerome Zeldis MD, PhD, who has been a director since June 22, 2011. Dr. Zeldis is currently Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation.
Soligenix operates in two divisions:
1. BioTherapeutics – focusing on orphan diseases and areas of unmet medical need
2. BioDefense – focusing on developing countermeasures for inclusion in the US Government’s Strategic National Stockpile
Soligenix is developing proprietary formulations of oral BDP for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including:
• Pediatric Crohn's disease (SGX203)
• Acute radiation enteritis (SGX201)
• Chronic Graft-versus-Host disease (orBec®)
Soligenix BioDefense Division is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile.
Soligenix's lead biodefense products in development are:
• RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin
• VeloThrax™, a vaccine against anthrax exposure
Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. To date, development of OrbeShield™ has been largely supported by a $1 million NIH grant to Soligenix's academic partner, the Fred Hutchinson Cancer Research Center.
Soligenix announced a worldwide exclusive collaboration with Intrexon Corporation that will focus on the joint development of a treatment for Melioidosis. Inxtrexon is run by billionaire R.J. Kirk, considered to be one of the most successful biotech company developers in the United States.
Use the Catalyst Corner Pair Tool to create your own paired stock position which consists of one long and one short security. The model is flexible as it allows you to decide which US listed stocks to pair against one another and how much capital you desire to employ per long position. The Pair Trading Tool’s output is detailed and clearly allows for fundamental and statistical comparison of a user defined pair.